• Helena

Mira Fertility Launches the First FDA and CE Registered Numeric Estrogen & Luteinizing Hormone Test

The new at-home tracking solution detects a woman's fertile window with >99% accuracy.

San Francisco-based FemTech company Mira, a leader in at-home testing solutions for women, has announced the launch of Mira Fertility Plus. The first at-home monitoring system to track both luteinizing hormone and estrogen levels in women, Mira Fertility Plus is Mira's second product to come to market. The hormone estrogen is a key component in understanding reproductive health and an integral part of the fertility process. Tracking both luteinizing hormone and estrogen levels allows women to detect and understand their fertile window and ovulation cycles. These hormone levels are related to IVF, menopause, as well as hormone imbalances such as PCOS, and other conditions.

This personalised ovulation monitoring system helps couples conceive using a highly accurate fluorescent-based test of the hormones. Since the launch of Mira in January 2018, thousands of women have used Mira to get pregnant or avoid pregnancy. The new Mira Fertility Plus Wand works with the original Mira analyser, making the Mira Analyzer a one-stop solution for a complete picture of the reproductive cycle and health. Later this year, Mira plans to expand the line to measuring progesterone, hCG, FSH as well as analysis for ovarian reserve, fetal health and miscarriage, menopause and hormone imbalances.

“It is important to know a woman’s cycle is more than just ovulation. The hormone regularity, profile and trend are strongly related to a woman’s health in general,” Said Sylvia Kang, co-founder, and CEO of Mira. “We want to arm women to know their bodies, become aware of any issues early, and ease the process of getting pregnant or avoiding pregnancy. Knowledge is power and being able to run analytics on your own health helps to make the right decisions and be proactive, which is a much needed complementary to mainstream medicine."

During this uncertain time, Mira’s mission to empower women to have a better understanding of their own health at home is even more important. Many fertility treatments were cancelled and postponed, forcing women to find a reliable at-home solution. In a recent study, Mira noticed a 31% increase in ovulation testing during the outbreak. Having a solution like Mira that shows the fertile window by tracking actual hormone levels can double a woman's chances of getting pregnant according to a recent study. Mira provides insights into how the female body works and helps with making decisions in the comfort of their home versus going to the doctor, with comparable lab-grade accuracy.

Emerging FemTech companies like Mira are trying to help women track, understand, and act on their personal health data. At-home solutions for tracking hormones with greater accuracy enables more opportunities for preventative medicine and diagnosis as virtual care and telemedicine are skyrocketing adoption. Hormones are in tight connection with our immune system and body. They deliver messages to organs and tell them what to do. Even small hormonal imbalances can lead to noticeable changes.


Mira is the first personalised, at-home, lab-quality hormone tracking system made for everyone’s unique fertility journey. Tracking numeric hormone levels and gaining real-time data to support every stage of a woman's fertility journey — with over 99% accuracy. OBGYN recommended and FDA approved.

The Mira Fertility Plus wands measure both numeric estrogen and LH hormones. New Mira Plus Wands work with the same Analyzer that Mira has. The Mira Fertility Plus consists of Mira Fertility Plus Wands that sample urine, a palm-sized and USB-charged Mira Analyzer device, and a smartphone app that uses cloud-based AI to personalise a woman's fertility cycle analysis. Users simply insert one of the disposable Mira Fertility Wands, after sampling a urine sample, into the Mira Analyzer’s test slot. Users will use approximately 10-15 Mira Wands per cycle.

The Mira Analyzer reads the fertility hormone level and displays on the analyser’s display screen the numeric hormone concentrations. It then sends the user’s personal quantitative hormone levels to the accompanying app, which analyses the data by the AI on the cloud and automatically tracks and predicts the individual’s cycle health.

For more information on Mira please visit miracare.com

For further press information, high res imagery or sample requests please contact:

Zoja Minic

+44 (0) 7715244678





Kingsway  Place

Block  B,  Studio  2a

Sans  Walk



Website designed by WHITEHAIR.CO

WHITEHAIR.CO is the trading name of Whitehair Co Limited

Registered in England & Wales

Company No: 08801233

VAT no: 170 6305 30 

+44 (0) 7715244678